此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy

2026年7月13日 更新者：RyCarma Therapeutics, Inc.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Surlorian (ARM210, S48168) in Adults With Autosomal Dominant RYR1-Related Myopathy

This study is testing a medicine called surlorian in adults who have a genetic muscle condition known as autosomal dominant RYR1-related myopathy (RYR1-RM). The goal is to find out whether surlorian improves muscle weakness, and whether it is safe and well tolerated.

研究概览

地位

招聘中

条件

干预/治疗

详细说明

The study is taking place at several medical centers with doctors who specialize in treating people with RYR1-RM. Everyone in the study will receive both surlorian and a placebo (a "dummy" treatment) at different times, but neither the participants nor the study staff will know which one they are getting during each period.

During Treatment period 1, participants will be randomly assigned to receive either surlorian or a placebo, which will be followed up by a washout period. Following the washout, in Treatment period 2, participants will switch and receive the opposite treatment from what they received in the first period. This main part of the study lasts about 16 weeks.

After finishing the main, placebo-controlled part of the study participants may be able to join an open-label extension lasting approximately 12 months. In this extension, everyone receives surlorian.

研究类型

介入性

注册 (估计的)

28

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

学习地点

  • 德国
    • Baden-Wurttemberg
      • Ulm、Baden-Wurttemberg、德国、89081
        • 尚未招聘
        • Universitätsklinikum Ulm
    • State of Berlin
      • Berlin、State of Berlin、德国、13125
        • 招聘中
        • Charité - Campus Berlin Buch
  • 法国
      • Paris、法国、73013
        • 尚未招聘
        • Institut de Myologie - Hôpital de La Pitié-Salpétrière
    • Bouches-du-Rhône
      • Marseille、Bouches-du-Rhône、法国、13385
        • 尚未招聘
        • AP-HM- Hôpital de La Timone
  • 英国
      • London、英国、WC1N 3BG
        • 招聘中
        • University College Hospital - PPDS
    • Shropshire
      • Oswestry、Shropshire、英国、SY10 7AG
        • 尚未招聘
        • The Robert Jones and Agnes Hunt Orthopaedic Hospital
  • 荷兰
    • Gelderland
      • Nijmegen、Gelderland、荷兰、6500 HB
        • 尚未招聘
        • Radboud Universitair Medisch Centrum
  • 西班牙
    • Barcelona
      • Barcelona、Barcelona、西班牙、8035
        • 尚未招聘
        • Hospital Universitario Vall d'Hebron - PPDS
    • Guipúzcoa
      • San Sebastián、Guipúzcoa、西班牙、20014
        • 尚未招聘
        • Hospital Universitario de Donostia

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Can understand the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with all protocol requirements
  • Confirmed genetic diagnosis of RYR1-RM with autosomal dominant mutation
  • Clinical evidence of weakness affecting any proximal muscle group(s) as assessed by the Investigator
  • Can walk 10 m with or without a cane (no other walking aid allowed)
  • Is either a female of non-childbearing potential or male or female, who agrees to use highly effective contraception/preventive exposure measures from the time of first dose of IP (for a male participant) or the signing of the informed consent form (ICF) (for a female participant) during the trial, and until 7 days after the last dose of IP.

Exclusion Criteria:

  • Unable or unwilling to understand and comply with protocol requirements or unlikely to complete the study as planned, as judged by the Investigator
  • Any clinically significant medical condition that, in the opinion of the Investigator, would interfere with the study
  • Females who are pregnant, breastfeeding or intend to become pregnant, or of childbearing potential not using adequate contraceptive methods
  • Participants with severe pulmonary dysfunction at screening, or evidence of pulmonary exacerbation (defined as an acute worsening of respiratory symptoms that result from a decline in lung function)
  • Cardiac disease by history or at screening that, in the Investigator's opinion, is likely to worsen overall performance of efficacy measures during the study
  • History of seizure disorder, neurologic disease, or neuromuscular disease other than RYR1-RM
  • History of chronic orthopedic issues, acute injury, or expected surgery during the study that may affect the ability to complete study assessments
  • Positive test results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)
  • Participants with screening alanine aminotransferase (ALT) levels >3 × upper limit of normal (ULN) or screening aspartate aminotransferase (AST) levels >5 × ULN (isolated elevations of total bilirubin <2 × ULN with direct bilirubin below the ULN will be included)
  • History within the past year of alcohol or other drug substance abuse
  • Known hypersensitivity to the investigational product of related compounds
  • Treatment with statins, proton pump inhibitors or H2 blockers within 7 days or 5 half-lives, whichever is longer, prior to the first dose of the study drug
  • Treatment with sensitive or narrow therapeutic index CYP3A4 substrates within 7 days or 5 half-lives, whichever is longer, prior to first dose of the study drug
  • Treatment with strong or moderate CYP2C8 inhibitor or inducers within 7 days or 5 half-lives, whichever is longer, prior to the first dose of the study drug
  • Currently enrolled in another study or received treatment with any other investigational drug within 30 days or > 5 half-lives, whichever is longer, prior to screening
  • Has reported any suicide ideation of Category 4 or 5 on the C-SSRS within 6 months prior to screening or any suicidal behavior in the last two years prior to screening as indicated by any 'yes' answers on the suicidal behavior section of the C-SSRS

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：交叉作业
  • 屏蔽：双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的：A组
药品：Surlorian
300 mg administered once a day
其他名称：
  • ARM210 (S48168)
安慰剂比较：B组
其他：Placebo
administered once a day

研究衡量的是什么？

主要结果指标

结果测量
大体时间
Change from baseline in the 1-minute sit-to-stand test (1-MSST)
大体时间：Day 1 to day 28 [approximately]
Day 1 to day 28 [approximately]

次要结果测量

结果测量
措施说明
大体时间
Change from baseline in the 6-Minute Walk Test (6-MNWT)
大体时间：Day 1 to day 28 [approximately]
Day 1 to day 28 [approximately]
Change from baseline in the Timed Up and Go Test (TUG)
大体时间：Day 1 to day 28 [approximately]
Day 1 to day 28 [approximately]
Change from baseline in the 4-Stair Climb Test (4-SCT)
大体时间：Day 1 to day 28 [approximately]
Day 1 to day 28 [approximately]
Change from baseline Quantitative Muscle Assessment (QMA)
大体时间：Day 1 to day 28 [approximately]
Day 1 to day 28 [approximately]
Change from baseline Manual Muscle Testing (MMT)
大体时间：Day 1 to day 28 [approximately]
Day 1 to day 28 [approximately]
Change from baseline in Patient-Reported Outcomes Measurement Information System-fatigue (PROMIS-F)
大体时间：Day 1 to day 28 [approximately]
Day 1 to day 28 [approximately]
Change from baseline in Patient-Reported Outcomes Measurement Information System-physical fatigue (PROMIS-PF)
大体时间：Day 1 to day 28 [approximately]
Day 1 to day 28 [approximately]
Chage in International Physical Activity Questionnaire (IPAQ)
大体时间：Day 1 to day 28 [approximately]
Day 1 to day 28 [approximately]
Number of Adverse Events
大体时间：Day 1 to end of study [approximately 68 weeks]
Day 1 to end of study [approximately 68 weeks]
Change from baseline in systolic blood pressure
大体时间：Day 1 to end of study [approximately 68 weeks]
Systolic blood pressure will be measured in millimeters of mercury (mmHg)
Day 1 to end of study [approximately 68 weeks]
Change from baseline in diastolic blood pressure
大体时间：Day 1 to end of study [approximately 68 weeks]
Diastolic blood pressure will be measured in millimeters of mercury (mmHg)
Day 1 to end of study [approximately 68 weeks]
Change from baseline in temperature
大体时间：Day 1 to end of study [approximately 68 weeks]
Temperature will be measured in degrees Centigrade (°C)
Day 1 to end of study [approximately 68 weeks]
Change from baseline in hemoglobin
大体时间：Day 1 to end of study [approximately 68 weeks]
Hemoglobin concentration will be measured in grams per liter (g/L) using standard hematology laboratory methods
Day 1 to end of study [approximately 68 weeks]
Change from baseline in white blood cell count
大体时间：Day 1 to end of study [approximately 68 weeks]
White blood cell count will be measured in ×10⁹/L using standard hematology laboratory methods
Day 1 to end of study [approximately 68 weeks]
Change from baseline in platelet count
大体时间：Day 1 to end of study [approximately 68 weeks]
Platelet count will be measured in ×10⁹/L using standard hematology laboratory methods
Day 1 to end of study [approximately 68 weeks]
Change from baseline in serum creatinine
大体时间：Day 1 to end of study [approximately 68 weeks]
Serum creatinine will be measured in micromoles per liter (µmol/L) using standard clinical chemistry methods
Day 1 to end of study [approximately 68 weeks]
Change from baseline in estimated glomerular filtration rate
大体时间：Day 1 to end of study [approximately 68 weeks]
Estimated glomerular filtration rate (eGFR) will be calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration equation
Day 1 to end of study [approximately 68 weeks]
Change from baseline in serum glucose
大体时间：Day 1 to end of study [approximately 68 weeks]
Serum glucose concentration will be measured in millimoles per liter (mmol/L) using standard clinical chemistry methods
Day 1 to end of study [approximately 68 weeks]
Change from baseline in QTc interval
大体时间：Day 1 to end of study [approximately 68 weeks]
Corrected QT interval (QTcF) will be measured in milliseconds using triplicate 12-lead electrocardiograms
Day 1 to end of study [approximately 68 weeks]
Change from baseline in urine protein
大体时间：Day 1 to end of study [approximately 68 weeks]
Urine protein will be measured in milligrams per liter (mg/L) using standard urinalysis methods
Day 1 to end of study [approximately 68 weeks]

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

RyCarma Therapeutics, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年7月1日

初级完成 (估计的)

2027年8月27日

研究完成 (估计的)

2028年8月27日

研究注册日期

首次提交

2026年4月7日

首先提交符合 QC 标准的

2026年4月23日

首次发布 (实际的)

2026年4月30日

研究记录更新

最后更新发布 (实际的)

2026年7月15日

上次提交的符合 QC 标准的更新

2026年7月13日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • CL2-210-02
  • 2025-522343-18-00 (克蒂斯)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅